The Filing Desk

Zai Lab

ZLAB · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ZLAB · Last close · November 19, 2026
$21.92
Value Zai Lab yourself

Zai Lab's revenue rose 15.3% to $460 million in fiscal 2025. Its operating margin was −49.9%, up from −70.7% a year earlier. Free cash flow was −$159 million. The diluted share count rose 10.7%.

ZAI LAB LIMITED Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001704292-26-000015 Updated
Revenue
$460M
15.3%
Operating margin
−49.9%
20.8 pts
Net income
−$176M
 
Free cash flow
−$159M
 
Return on equity
−22.6%
8.9 pts
Market cap
$24.6B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (10-for-1), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Zai Lab lost money in fiscal 2025: a net loss of $176 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,4091,008806780690
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage———−125.2x−44.0x
Current ratio7.8x8.0x4.6x3.5x2.5x
Quick ratio7.7x7.8x4.4x3.4x2.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, billions

Projections

Project Zai Lab's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $65,804 of Zai Lab shares on the open market, and 6 insiders sold $11.1 million, $9.2 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 19, 2026Yajing ChenChief Financial OfficerSold plan260$27.00$7,020Form 4
Aug 12, 2026William LisDirectorSold plan8,506$25.00$212,650Form 4
Aug 11, 2026Yajing ChenChief Financial OfficerSold plan619$25.00$15,475Form 4
Jul 1, 2026Richard GaynorDirectorBought plan1,736$19.05$33,071Form 4
Jun 30, 2026Ying DuChairperson & CEO, DirectorSold7,026$18.53$130,192Form 4
Jun 26, 2026Ying DuChairperson & CEO, DirectorSold24,543$17.46$428,521Form 4
Jun 26, 2026Frazor Titus Edmondson IIIChief Legal OfficerSold4,103$17.46$71,638Form 4
Jun 26, 2026Yajing ChenChief Financial OfficerSold2,264$17.46$39,529Form 4
Jun 22, 2026William LisDirectorSold plan7,040$18.09$127,354Form 4
May 18, 2026Ying DuChairperson & CEO, DirectorSold plan50,000$19.00$950,000Form 4
May 15, 2026Ying DuChairperson & CEO, DirectorSold plan50,000$20.74$1.0 millionForm 4
May 14, 2026Ying DuChairperson & CEO, DirectorSold plan50,000$20.09$1.0 millionForm 4
The latest 12 of 39 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−53.0%−5.7%−19.2%
Altman Z''−1.14−1.63−3.61
Accruals ratio−12.1%−3.8%−2.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin roseFailFailFail
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Zai Lab side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Zai LabFY2515.3%−49.9%−34.5%———
Travere TherapeuticsFY25110.5%−12.8%———7Compare
BridgeBio PharmaFY25126.3%−104.2%−89.0%——3Compare
InnovivaFY2514.7%39.8%47.6%17.9%—6Compare
ArdelyxFY2522.1%−10.1%−10.8%−36.1%—2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue——01349144215267399460
Revenue growth———9,965.9%277.0%194.8%49.0%24.0%49.6%15.3%
Gross profit——093292141171252270
Research and development3239120142223573286266234221
Operating income−38−51−142−203−302−700−404−367−282−229
Net income−38−50−139−195−269−704−443−335−257−176
Diluted EPS (US$)−0.40−0.23−0.26−0.30−0.35−0.76−0.46−0.35−0.26−0.16
Diluted shares (millions)942185266447779309589669901,095
Cash flow
Cash from operations−32−32−98−191−216−549−368−198−215−151
Capital expenditure29106101825768
Free cash flow−34−41−108−197−226−568−392−205−221−159
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation5101220254161807166
Balance sheet at fiscal year end
Cash and short-term investments842302632761,1871,4091,008806780690
Debt incl. finance leases——————————
Total assets892503023551,2981,6101,2201,0361,1861,172
Total liabilities6145160128230174240345457
Shareholders' equity−522352512951,1691,3801,046796841716
Margins and ratios
Gross margin——66.6%71.1%65.8%63.8%65.6%64.1%63.1%58.6%
Operating margin——−109,897.7%−1,564.8%−616.5%−485.1%−188.0%−137.4%−70.7%−49.9%
Net margin——−107,810.1%−1,502.3%−549.3%−488.2%−206.1%−125.5%−64.4%−38.1%
Free cash flow margin——−83,374.4%−1,517.5%−462.0%−393.3%−182.4%−77.0%−55.3%−34.5%
Rule of 40 (growth + FCF margin)———8,448.4%−185.0%−198.5%−133.4%−53.0%−5.7%−19.2%
Return on capital——————————
Return on equity—−54.9%−57.2%−71.5%−36.7%−55.3%−36.5%−36.3%−31.4%−22.6%
Return on assets—−29.8%−50.4%−59.4%−32.5%−48.5%−31.3%−29.7%−23.1%−14.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Zai Lab's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Zai Lab.